MedTrace Logo

Apatinib Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR WT, Non-squamous NSCLC

NCT02852798 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2016-08-03

No results posted yet for this study

Summary

This is a clinical study of Apatinib Mesylate Tablets combined with docetaxel monotherapy as second-line therapy of advanced EGFR wild-type, non-squamous, non-small-cell lung cancer.

Conditions

  • Nonsquamous Nonsmall Cell Neoplasm of Lung

Interventions

DRUG

Apatinib Combined With Docetaxel

Docetaxel 75 mg/ (m2.d)IV gtt 1h d1 q3w Apatinib Mesylate Tablets : 500 mg qd, 4 weeks as one cycle for continuous drug administration

Sponsors & Collaborators

  • Dongguan People's Hospital

    collaborator OTHER_GOV

  • Jiangsu ShengDiYa Medicine Co., Ltd.

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2017-08-31
Completion
2018-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02852798 on ClinicalTrials.gov